-+ 0.00%
-+ 0.00%
-+ 0.00%

Atrium Therapeutics earns $15 million milestone payment from Bristol Myers Squibb

PUBT·04/23/2026 12:05:17
Listen to the news
Atrium Therapeutics earns $15 million milestone payment from Bristol Myers Squibb
  • Atrium Therapeutics earned a USD 15 million development milestone payment from Bristol Myers Squibb under a global cardiovascular collaboration.
  • Milestone triggered by delivery of a development candidate for first licensed compound targeting a cardiology indication.
  • Agreement terms include eligibility for up to about USD 1.35 billion in research and development milestones.
  • Commercial milestones could reach about USD 825 million, with tiered royalties up to low double-digits on net sales.
  • Bristol Myers Squibb will fund future clinical development, regulatory work, and commercialization tied to collaboration programs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.